tirzepatide surpass-4 versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial Frias_Tirzepatide: Overview of SURPASS Trials
Description
Eligibility restrictions apply, and this program is not available to Medicare, Medicaid, or federal healthcare program participants
Retatrutide dosage escalation (Phase 2 trial protocol) The Phase 2 trial tested multiple starting dose strategies
There is no dose dialing required
In the SURPASS program, gastrointestinal side effects associated with the use of tirzepatide were similar to those observed with semaglutide and GLP1-RA drugs in general, both in terms of frequency and duration [3]
Key Differences Between Ozempic, Wegovy, Rybelsus, and Mounjaro Active Ingredients Ozempic and Wegovy both contain semaglutide
Every missed weekly injection represents 14% of monthly treatment absent
